glp 1 cvs caremark Reminder: will administer the GIC's prescription drug benefit for non-Medicare health insurance plans effective July 1, 2023 CVS Caremark Sued: Zepbound Patients

Tirzepatide (Mounjaro) is a dual agonist targeting both GLP-1 and GIP receptors, which tends to produce greater weight loss

Increased appetite/weight gain (reduced via central satiety and delayed gastric emptying)

How much does Mounjaro cost with Blue Cross Blue Shield

Ozempic Lawsuit Background Ozempic lawsuits claim that Novo Nordisk, Ozempics manufacturer, failed to warn patients of the possibility of developing DVT or PE after taking the drug

However Lillys demonstration that a GIP/GLP-1 receptor co-agonist (tirzepatide) has superior efficacy compared to selective GLP-1 receptor agonists, has renewed interest in the first incretin. Lilly rolled out their SURPASS trials to position their agent amongst existing diabetes medications and GLP-1 agonists

Risks were increased for preterm delivery (17% vs 13%